Investor Relations

Overview

PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders, among others.

For Investor Relations inquiries, please contact PureTech's Investor Relations team at: ir@puretechhealth.com.

For more information, please use the links to the right.

View our corporate deck.

Share Price

Half Year Report 2021

View Here

Corporate Presentation

View Here

Cash at PureTech Parent Level

$409.7M PureTech Level Cash and Cash Equivalents as of June 30, 2021¹

1. PureTech Level Cash Reserves at September 30, 2020 represent cash balances and short-term investments held at PureTech Health LLC, PureTech Management, Inc., PureTech Health PLC, PureTech Securities Corporation of $372.0 million and held at PureTech LYT Inc., our internal pipeline, of $15.2 million, all of which are wholly owned entities of PureTech, excluding cash balances and short-term investments of $38.3 million held at Controlled Founded Entities which are not wholly owned.

Advisors

SOLICITORS
DLA Piper UK LLP
3 Noble Street
London EC2V 7EE
United Kingdom
TEL: +44 870 011 1111

INDEPENDENT AUDITOR
KPMG LLP
15 Canada Square
London E14 5GL
United Kingdom
TEL: +44 207 311 1000

MEDIA / PR
FTI Consulting, Inc.
200 Aldersgate
Aldersgate Street
London EC1A 4HD
United Kingdom
TEL: +44 203 727 1000

Registrar

Our share register is managed and administered by Computershare Investor Services PLC.
Computershare Investor Services PLC should be able to help you with most questions you may have about your PureTech Health PLC shares.

Computershare Investor Services PLC
The Pavilions, Bridgwater Road
Bristol BS99 6ZZ
United Kingdom

Telephone UK: 0800 408 0094
Telephone Overseas: +44 870 889 3159
Email: web.queries@computershare.co.uk